clinical trial · NCT05877547
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
Merck Sharp & Dohme LLC·phase2·completed·n = 381
Non-alcoholic Fatty Liver DiseaseFatty Liver, NonalcoholicNAFLDNonalcoholic Fatty Liver DiseaseNonalcoholic SteatohepatitisEfinopegdutideSemaglutidePlacebo
brief summary
The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Researchers will also learn about the safety and benefit of efinopegdutide and how well people tolerate the medicine. The main goal of the study is to compare how many people taking efinopegdutide or placebo stop showing evidence of NASH without liver scarring getting worse.
started
Jun 23, 2023
primary completion
Dec 29, 2025
completion
Dec 29, 2025
last updated
Jan 12, 2026
official title
A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic Steatohepatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol